Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx

Posted inBiotechnology

Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.